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Abstract Vpr is a HIV-1 virion-associated protein which plays
a role in viral replication and in transcription and cell
proliferation. We have previously reported that Vpr stimulates
transcription of genes lacking a common DNA target sequence
likely through its ability to interact with TFIIB. However, the
molecular mechanism of the Vpr-mediated transcription remains
to be precisely defined. In this in vitro study, we show that the
binding site of Vpr in TFIIB overlaps the domain of TFIIB which
is engaged in the intramolecular bridge between the N- and C-
terminus of TFIIB, highly suggesting that binding of Vpr may
induce a change in the conformation of TFIIB. Indeed, with a
partial proteolysis assay using V8 protease, we demonstrate that
Vpr has the ability to change the conformation of TFIIB. We
investigated in this partial proteolysis assay a series of Vpr-
mutated proteins previously defined for their transactivation
properties. Our data show a correlation between the ability of
Vpr-mutated proteins to stimulate transcription and their ability
to induce a conformational change in TFIIB, indicating a
functional relevance of the Vpr-TFIIB interaction.
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1. Introduction
The HIV-1 genome encodes, in addition to gag, pol and env
structural gene products common to all retroviruses, accessory
gene products which are dispensable for in vitro viral repli-
cation but are believed to be important in optimizing the viral
life cycle in vivo (for a review, see [1]). Among them, the Vpr
protein, which is encoded by an open reading frame located in
the central part of the viral genome, is of particular interest. It
is one of the HIV-1 non-structural proteins that is incorpo-
rated into the viral particles in molar concentrations, strongly
suggesting a role in the immediate early events upon infection
of permissive cells [2]. In infected cells, Vpr accumulates in the
nuclei. Results from a number of studies have revealed that
Vpr has several properties. Vpr has been shown to be impor-
tant in the viral life cycle in facilitating nuclear import of the
HIV-1 DNA in newly infected cells, thus allowing infection of
non-dividing macrophages [3^7]. Expression of Vpr results in
arrest of the cell cycle in the G2/M phase [8^11], induces
terminal di¡erentiation in some cell lines [12] and enhances
viral replication through its transcriptional properties [13].
We have previously shown that Vpr co-operates with di¡er-
ent heterologous promoter-bound activator domains to stim-
ulate transcription [14]. These results, in addition with those
from Cohen et al. [13], have demonstrated that the transacti-
vation property of Vpr does not seem to depend on speci¢c
responsive promoter sequences. Other studies have indicated
that Vpr interacts with the ubiquitous cellular transcription
factor Sp1 [15] or with the glucocorticoid receptor [16,17].
Moreover, we have demonstrated that Vpr speci¢cally binds
to the general transcription factor TFIIB, indicating that Vpr
functions as a transcriptional co-activator [14]. These data,
con¢rmed recently by Kino et al. [17], suggest that the Vpr-
mediated transcription requires interactions with speci¢c tran-
scription factors and/or with the basal transcription machi-
nery.
Although Vpr has a transcriptional e¡ect on several pro-
moters, the molecular basis for this activity is unclear. In this
study, we investigate the functional relevance of the Vpr-
TFIIB interaction. Our data led us to propose a molecular
mechanism by which Vpr may function as a co-activator of
several heterologous promoters.
2. Materials and methods
2.1. Plasmid constructions
The NL43 Vpr wild-type expression plasmid was used as a template
to generate mutated Vpr sequences using a two-step recombinant
PCR methodology. PCR-ampli¢ed products were then cloned after
appropriate enzymatic digestion between BamHI and NotI restriction
sites of the pGEX-5X-2 plasmid (Pharmacia). GST-Vpr derivatives
were named E25K, A30F, V57L and R80A. GST-TFIIB expression
plasmid (a kind gift of E. Manet) was used to generate GST-TFIIB
derivatives by PCR-assisted in vitro mutagenesis. GST-TFIIB deriva-
tives were named W52A, F52A, W52A/F55A, R53A/T54A and E51A/
S65A. GST and GST-Vpr open reading frames have been previously
described [14] and were subcloned between NcoI and XhoI restriction
sites into the Pos7 expression vector (kindly provided by B. Moss) and
expressed in HeLa cells under the control of the T7 polymerase pro-
moter.
2.2. Analysis of Vpr-TFIIB complexes in cells
To overexpress GST or GST-Vpr, HeLa cells previously infected
for 1 h with three plaque forming units of recombinant vaccinia virus
(T7-VTF, Ankara strain: a kind gift of G. Sutter) per cell, were trans-
fected with GST or GST-Vpr genes cloned into the Pos7 expression
vector. Cells overexpressing GST or GST-Vpr were harvested 24 h
after transfection and lysed by freeze-thawed cycles in a bu¡er con-
taining 20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 0.1 mM EDTA,
1 mM DTT, 0.5% of NP-40 in the presence of an anti-protease cock-
tail. Expression of the GST derivatives in cell lysates was detected by
Western blotting with anti-GST antibody (Santa Cruz Biotechnolo-
gies). Expression of Vpr fused to GST was detected in cell lysates by
Western blotting with our anti-Vpr antibody obtained from rabbits
injected with puri¢ed MBP-Vpr fusion protein. Endogenous expres-
sion of TFIIB in cell lysates was detected by Western blotting with
anti-TFIIB antibody (Santa Cruz Biotechnologies). Upon 30 min in-
cubation on ice, cell lysate was diluted ¢ve times with the same bu¡er
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without NP-40 and incubated for 2 h before addition of GSH-agarose
beads. Beads were then recovered by centrifugation and after exten-
sive washes, bound proteins were resolved by SDS-PAGE followed by
Western blotting analysis with anti-TFIIB antibody.
2.3. In vitro protein-protein binding assays
GST fusion protein expression plasmids were grown in the Esche-
richia coli TG1 strain. Transformed bacteria were induced with iso-
propyl-L-D-thiogalactopyranoside for 2^3 h. The induced bacteria
were resuspended in phosphate-bu¡ered saline bu¡er (PBS) contain-
ing 1% Triton X-100 and lysed by sonication. Insoluble material was
pelleted and supernatants were adjusted to 10% glycerol and stocked
at 370‡C. The bacterial lysate expressing GST fusion proteins was
incubated with glutathione (GSH)-agarose beads (Sigma) at 4‡C for
1 h and then extensively washed. GST-Vpr derivatives immobilized on
GSH beads were incubated in a bu¡er containing 50 mM Tris-HCl
pH 7.9, 0.2 mM EDTA, 0.5 mM PMSF, 2 mM DTT, 100 mM KCl,
0.3% NP-40 and 1 mg/ml BSA, in the presence of recombinant TFIIB
(Santa Cruz Biotechnologies). After extensive washes, bound proteins
were resolved by SDS-PAGE, electro-transferred to PVDF mem-
branes (Amersham) and then processed for Western blotting using
rabbit anti-TFIIB antibody (C18, Santa Cruz Biotechnologies) and
horseradish peroxidase-linked swine anti-rabbit immunoglobulin
(DAKO). Antibody binding was detected with ECL Western blotting
detection reagents (Amersham). GST-TFIIB derivatives immobilized
on GSH beads were incubated in a bu¡er containing 50 mM Tris-HCl
pH 7.6, 150 mM NaCl, 0.2% Tween-20 and BSA (200 Wg/ml) in the
presence of [35S]Vpr. In vitro translated, radiolabelled Vpr was ob-
tained as previously described [14]. Beads were extensively washed and
bound proteins were resolved by SDS-PAGE and revealed by auto-
radiography.
2.4. V8 protease assay
This assay was performed as described [18]. 20 ng of recombinant
TFIIB (Santa Cruz Biotechnologies) was incubated with increasing
amounts (1, 2 or 4 Wg) of GST derivatives immobilized on gluta-
thione-agarose beads. The total protein concentration was maintained
at 4 Wg by the addition of GST-immobilized glutathione-agarose
beads. Incubation was carried out for 1 h on ice in 40 mM HEPES,
pH 7.5, 120 mM KCl, 5 mM MgCl2, 0.5 mM EDTA, 1 mM DTT and
0.05% NP40, after which 10 ng of Staphylococcus aureus V8 protease
(Sigma) was added and the samples were incubated at 30‡C for an
additional 15 min. Digestion was stopped by adding SDS-PAGE
loading dye followed by incubation for 5 min at 100‡C. Proteolytic
fragments were resolved by 12% SDS-PAGE and visualized by immu-
noblotting using a rabbit polyclonal anti-TFIIB raised against a pep-
tide corresponding to amino acids 299^316 mapping near the carboxy-
terminus of human TFIIB (C18, Santa Cruz Biotechnologies) and
horseradish peroxidase-linked swine anti-rabbit immunoglobulin
(DAKO). Antibody binding was detected with ECL Western blotting
detection reagents (Amersham).
3. Results and discussion
3.1. Vpr and TFIIB interact in cells
We have previously demonstrated that the HIV-1 Vpr pro-
tein functions as a transcriptional co-activator through inter-
action with the RNA polymerase II initiation factor TFIIB
[14]. We investigated the biological relevance of these inter-
actions by purifying protein-protein complexes present in cell
extracts. GST or GST-Vpr fusion proteins were over-ex-
pressed in recombinant vaccinia virus-infected HeLa cells.
The expression in cell extracts of ectopic Vpr and endogenous
TFIIB was demonstrated by Western blotting (Fig. 1a). Cell
extracts expressing GST or GST-Vpr were incubated with
agarose-GSH beads. After extensive washes, bound proteins
were eluted and separated by SDS-PAGE followed by West-
ern blotting analysis with anti-TFIIB antibody. As shown in
Fig. 1b, the TFIIB protein is present in the precipitated com-
plexes containing GST-Vpr, and not in those containing GST,
con¢rming that a speci¢c interaction between TFIIB and Vpr
takes place in human cells. These data indicate that fusion of
Vpr with GST does not a¡ect its ability to associate with
TFIIB. In agreement with these data, the Vpr-TFIIB interac-
tion has recently been revealed by co-immunoprecipitation
experiments and an increase of the Vpr-TFIIB interaction
has been observed in the presence of dexamethasone [17].
3.2. The domain of Vpr involved in the Vpr-TFIIB interaction
Vpr contains in its N-terminal region an amphipatic K-hel-
ical domain spanning residues 17^34, which is important for
incorporation of Vpr into viral particles [19^21]. A second K-
helix containing a stretch of leucine/isoleucine residues acting
as a leucine zipper and involved in the dimerization of Vpr
has recently been reported by the analysis of the NMR-de-
rived structure of the C-terminal domain of Vpr (residues 52^
96) [22]. The C-terminal domain of Vpr contains several basic
residues which are involved in the Vpr-mediated cell cycle
arrest [19,23,24]. We investigated a series of Vpr-mutated pro-
teins for their ability to bind to TFIIB. The vpr genes con-
taining appropriate substitutions were inserted into a GST
fusion expression vector and bacterially expressed as GST
fusion proteins. In vitro protein-protein interactions were per-
formed by incubation of similar amounts of GST-Vpr mutant
fusion proteins with recombinant TFIIB. Bound proteins were
resolved by SDS-PAGE and revealed by Western blotting
with anti-TFIIB antibody. As shown in Fig. 2a, wild-type
Vpr, E25K, A30F and V57L Vpr mutants bind to TFIIB as
e⁄ciently as wild-type Vpr. In contrast, the R80A Vpr mutant
was clearly a¡ected in its binding to TFIIB. These results
indicate that a point mutation in the C-terminal basic domain
of Vpr signi¢cantly impaired the Vpr-TFIIB interaction.
3.3. The domain of TFIIB involved in the Vpr-TFIIB
interaction
Using a phage display assay, we have recently shown that a
consensus WxxF motif is a target for Vpr [25]. Amino acid
sequence analysis of TFIIB reveals that a WxxF motif is lo-
cated in the N-terminus of the molecule (residues 52^55). We
constructed a series of GST-TFIIB proteins mutated in the
WxxF motif, either at the W and/or F residues (W52A, F55A
Fig. 1. Vpr and TFIIB co-precipitates in cells. Vaccinia virus-in-
fected HeLa cells were transfected with expression plasmids encod-
ing GST or GST-Vpr under the control of the T7 polymerase pro-
moter. (a) Cells were lysed in lysis bu¡er and cell lysate was
analyzed by Western blotting with anti-GST, anti-Vpr and anti-
TFIIB antibody. (b) GST and GST-Vpr expressed in cell lysate
were precipitated by addition of GSH-agarose beads. Beads were
then extensively washed and bound proteins were resolved by SDS-
PAGE and revealed with anti-TFIIB antibody. Mr: molecular mass
markers (in kDa).
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and W52A/F55A) or at residues xx inside the motif (R53A/
T54A) or at residues outside the motif (E51A/S56A) (Fig. 2b,
top panel). GST, GST-TFIIB wild-type or mutated proteins
were incubated with [35S]Vpr and bound labelled proteins
were resolved by SDS-PAGE and revealed by autoradiogra-
phy. As shown in Fig. 2b, bottom panel, wild-type TFIIB
binds Vpr, but the introduction of mutations in the WxxF
motif of TFIIB dramatically decreased the Vpr binding, while
mutations located outside the motif had no e¡ect on the bind-
ing of Vpr.
Interestingly, it has been reported that native TFIIB is in a
‘closed’ conformation due to an intramolecular bridge be-
tween its N-terminus (residues 24^65) and the C-terminus
(residues 202^297) [18]. Disruption of the TFIIB intramolec-
ular bridge upon binding of the herpes virus VP16 transacti-
vator induces a change in the conformation of TFIIB. This
conformational change in TFIIB has been proposed to facil-
itate further assembly of TFIIF and RNA polymerase II al-
lowing stimulation of transcription. Our data indicating that
the position of the Vpr binding site in the N-terminus of
TFIIB (residues 52^55) overlaps the domain involved in the
intramolecular bridge (residues 24^65) suggest that Vpr may
have the ability to induce a change of conformation in TFIIB.
3.4. Vpr induces a conformational change in TFIIB
Recombinant TFIIB was subjected to limited digestion with
S. aureus V8 protease, in the presence of increasing amounts
of GST-Vpr wild-type or GST-Vpr-mutated proteins immobi-
lized on glutathione-agarose beads as previously described
[18]. After incubation, proteolytic products were resolved by
SDS-PAGE and visualized by immunoblotting with an anti-
body raised against the C-terminal part of TFIIB. As shown
in Fig. 3a, incubation of TFIIB with protease and increasing
amounts of GST-Vpr wild-type, but not GST, led to the in-
duction of a single proteolytic cleavage product which was
Vpr concentration-dependent (¢lled arrow), in addition to
the initial proteolytic cleavage products (approximately 27^
28 kDa and 17^18 kDa, open arrows). The di¡erence in the
TFIIB digestion pattern must re£ect di¡erences in the access-
ibility of V8 protease to proteolysis sites in the TFIIB-Vpr
complexes. The slight variations of the intensity of the initial
proteolytic cleavage products of TFIIB were Vpr concentra-
tion-independent and therefore not induced by Vpr. More-
over, we assume that it is likely the binding of Vpr to TFIIB
which masked the 27^28 kDa product because this product
remains unchanged in the presence of the R80A Vpr mutant
which is impaired for binding to TFIIB (Fig. 3b). The Vpr-
induced proteolytic cleavage product was not observed when
TFIIB was incubated with 4 Wg of GST-Vpr in the absence of
protease (data not shown). The size of the Vpr-induced frag-
ment indicates that the proteolytic cleavage site is located in
the N-terminal domain of TFIIB. Under the same conditions,
incubation of TFIIB in the presence of protease and increas-
ing amounts (1, 2 and 4 Wg) of GST-VP16, but not GST, led
to the induction of a major TFIIB proteolytic cleavage prod-
uct which was VP16 concentration-dependent, con¢rming pre-
vious data [18] indicating that VP16 has the ability to change
the conformation of TFIIB (data not shown).
We next investigated in this proteolysis assay some Vpr-
mutated proteins, previously de¢ned for their ability to stim-
ulate transcription [26]. As shown in Fig. 3b, E25K and V57L
Vpr proteins were able to induce increasing amounts of the
TFIIB proteolytic cleavage product (¢lled arrow). The Vpr
R80A mutant which was impaired to bind to TFIIB was
impaired to induce a TFIIB proteolytic cleavage product, in-
dicating that the Vpr-induced proteolytic cleavage site was
dependent on the interaction between Vpr and TFIIB.
Although able to bind to TFIIB, increasing amounts of the
Vpr A30F mutant did not induce increasing amounts of a
proteolytic cleavage product, indicating that this mutant was
unable to induce a conformational change in TFIIB. Alto-
gether, these data indicate that E25K and V57L Vpr mutants,
but not A30F and R80A Vpr mutants, are fully competent to
bind to and to induce a conformational change in TFIIB.
A correlation between the induction of a conformational
change in TFIIB and the stimulation of transcription has
been reported [18]. E25K and V57L Vpr mutants have been
reported to stimulate transcription of HIV-1 LTR as e⁄-
ciently as wild-type Vpr, while A30F and R80A Vpr mutants
were signi¢cantly impaired to stimulate transcription [26]. In-
terestingly, our results indicate a direct correlation between
the ability of Vpr to induce a conformational change in TFIIB
Fig. 2. Domains of Vpr and TFIIB involved in the Vpr-TFIIB in-
teraction. (a) Equivalent amounts (2 Wg) of GST and GST-Vpr mu-
tated fusion proteins immobilized on GSH beads were incubated
with 50 ng of recombinant TFIIB, bound proteins were resolved on
SDS-PAGE and revealed by Western blotting with a rabbit poly-
clonal anti-TFIIB antibody. GST-VP16 protein was used as a posi-
tive control. Lane marked input represents 10 ng of rTFIIB. (b) Top
panel: schematic diagram of the GST-TFIIB mutant proteins used
to map the Vpr binding site in TFIIB. The region containing the
WRTF motif in the N-terminal domain is represented as a hatched
box and introduced point mutations are indicated. Bottom panel:
equivalent amounts of GST and GST-TFIIB wild-type or mutated
proteins were a⁄nity-puri¢ed on GSH-agarose beads and incubated
with the in vitro translated radiolabelled Vpr protein. Bound pro-
teins were separated by SDS-PAGE and the gel was autoradio-
graphed. The lane marked input contains 40% of [35S]protein prior
to binding experiments. Mr: molecular mass markers (in kDa).
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and its ability to stimulate transcription. Indeed, E25K and
V57L Vpr mutants which were able to induce a TFIIB con-
formational change were able to transactivate. A30F and
R80A Vpr mutants which were impaired to induce a TFIIB
conformational change were signi¢cantly impaired to trans-
activate. These data provide a possible molecular mechanism
by which Vpr mediated the HIV-1 LTR transcription through
induction of a functional change in the conformation of
TFIIB. The possibility that Vpr stimulates transcription
through a distinct pathway cannot be ruled out. Indeed, it
has been reported that the R80A mutation in Vpr, although
a¡ecting the Vpr-mediated transcription of HIV-1 LTR, has
no e¡ect on the Vpr-mediated transcription of the glucocorti-
coid responsive genes [17,27]. The opposite e¡ects in the stim-
ulation of transcription observed for this mutant seems to be
dependent on the nature of the promoter, suggesting that Vpr
may activate the transcriptional process by alternative path-
ways. The Vpr-mediated transcription of the glucocorticoid
responsive genes in the presence of dexamethasone requires
a direct interaction of Vpr with the promoter-bound gluco-
corticoid receptor. It is likely that the interaction of Vpr with
the activator may be more important for stimulation of tran-
scription than the interaction of Vpr with TFIIB. In agree-
ment with this hypothesis, the R80A Vpr mutant which binds
to the glucocorticoid receptor, and not to TFIIB, still retains
its ability to transactivate glucocorticoid responsive genes. In
contrast, the L64A Vpr mutant, which is impaired to bind to
the glucocorticoid receptor, but still binds to TFIIB, is im-
paired for the glucocorticoid-activated transcription.
The contribution of the co-activator activity of Vpr remains
to be de¢ned in the context of HIV-1 replication. The viral
genome-encoded transactivator Tat and several cellular tran-
scription factors are required for e⁄cient HIV-1 expression
[28]. It is unknown how the viral genome initiates early tran-
scription of the viral genes immediately after viral entry when
Tat is at a suboptimal level. Vpr is a virion-associated protein
and consistent with this localization, it could play a critical
role in HIV-1 replication during early stages of HIV-1 infec-
tion. It is possible that Vpr a¡ects qualitatively TFIIB assem-
bly by inducing the conformational change in TFIIB, driving
pre-initiation complex assembly forward. The weak Vpr-in-
duced level of transcription could be su⁄cient to allow Tat
expression and full stimulation of the HIV-1 LTR transcrip-
tion. Whether the expression of Vpr a¡ects also quantitatively
TFIIB assembly by recruiting TFIIB into the pre-initiation
complex will require further studies. In addition to its role
in modulating the transcription of HIV-1 LTR, it is conceiv-
able that the co-activator function of Vpr a¡ects the tran-
scription of several cellular promoters thus deregulating cel-
lular gene expression in infected cells. Indeed, Vpr has been
demonstrated to suppress some cytokines expression through
its ability to indirectly alter the NF-KB activity [29]. Vpr has
been reported to be a secreted protein [30,31] suggesting that
it could deregulate cellular gene expression in uninfected cells
contributing to the pathogenesis of AIDS.
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